CTOs on the Move

Epic Pharmacy Network

www.epicrx.com

 
Formed in 1982 and headquartered in Maryland, EPIC Pharmacies is a not-for-profit buying group of hundreds of independently owned pharmacies across the country. EPIC offers a full range of programs and services while returning its net revenues to its members throughout the year, including a year-end distribution.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.epicrx.com
  • 5024 Campbell Boulevard Suite R
    Nottingham, MD USA 21236
  • Phone: 804.379.9060

Executives

Name Title Contact Details
Luke Gordon
 Vice President of Network Development Profile

Similar Companies

Cylene Pharmaceuticals

Cylene Pharmaceuticals Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharma Pac

Pharma Pac is a De Kalb, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspen Pharmacare Canada

We have a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products. As a leading global player in specialty, branded and generic pharmaceuticals, we have an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. We continue to increase the number of lives benefiting from our products that reach more than 150 countries. In line with the our commercial, production and territorial strategies, we have identified Thrombosis, Anaesthetics, High Potency & Cytotoxics as our focused therapeutic categories that will receive our highest focus based on materiality and future potential.

STAQ PHARMA

A brand new 503B outsourcing facility.

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).